Intracellular nanobody targeting T4SS effector inhibits ehrlichia infection
AssigneeOhio State Innovation Foundation
InventorsYasuko Rikihisa, Wenqing Zhang
Life of this patent
Estimating the term…
Abstract
Infection with obligatory intracellular bacteria is difficult to treat as intracellular targets and delivery methods of therapeutics are not well-known. Ehrlichia translocated factor-1 (Etf-1), a type IV secretion system (T4SS) effector, is a primary virulence factor for an obligatory intracellular bacterium, Ehrlichia chaffeensis. Disclosed herein are Etf-1-specific nanobodies (Nbs) that block Etf-1 functions and Ehrlichia infection. Also disclosed is a method for treating human monocytic ehrlichiosis (HME) in a subject with the disclosed nanobodies.
Claims7
A composition comprising a nanobody, wherein the nanobody comprises CDR1, CDR2, and CDR3 sequences, wherein the CDR1 sequence of the VH domain comprises the amino acid sequence GGTLSSYT (SEQ ID NO:30), the CDR2 sequence of the VH domain comprises the amino acid sequence VARVNGRI (SEQ ID NO:31), and the CDR3 sequence of the VH domain comprises the amino acid sequence AAQEFGYTGGISRAISDYDY (SEQ ID NO:32).
Dependencies are inferred from the claim text.